Renal Outcomes in People With HIV-1 and Renal Impairment Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide: Integrated Analysis From 9 Phase 3/3b Clinical Trials

Authors

• Frank A Post
• David Wohl
• Geoffroy Liegeon
• Indira Brar, Henry Ford HealthFollow
• Debbie Hagins
• Yazdan Yazdanpanah
• Anchalee Avihingsanon
• Hui Liu
• Keith Aizen
• Jason T Hindman
• Samir Gupta

Recommended Citation

Post FA, Wohl D, Liegeon G, Brar I, Hagins D, Yazdanpanah Y, Avihingsanon A, Liu H, Aizen K, Hindman JT, Gupta S. Renal Outcomes in People With HIV-1 and Renal Impairment Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide: Integrated Analysis From 9 Phase 3/3b Clinical Trials. Open Forum Infect Dis. 2026;13(5):ofag265.

Document Type

Article

Publication Date

5-1-2026

Publication Title

Open Forum Infect Dis

Abstract

Among 1069 people with HIV-1 and mild to moderate renal impairment at baseline treated with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) across 9 clinical trials, renal function remained generally stable over follow-up of up to 240 weeks. Renal adverse events were infrequent, and discontinuation due to renal toxicity was rare.

PubMed ID

42182842

Volume

13

Issue

5

First Page

265

Last Page

265